Vivos Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst on September 9. Analyst Lucas Ward from Ascendiant maintained a Buy rating on the stock and has a $6.50 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lucas Ward has given his Buy rating due to a combination of factors that highlight Vivos Therapeutics’ strategic pivot and growth potential. The company’s recent acquisition of The Sleep Center of Nevada is a significant move, as it represents a shift from relying solely on dentists to a more diversified approach that includes direct patient relationships through sleep centers. This acquisition is expected to unlock new revenue streams by leveraging the existing customer base for upselling Vivos’ FDA-approved solutions for obstructive sleep apnea (OSA).
Furthermore, Vivos is actively expanding its partnerships with sleep testing centers nationwide, aiming to capture a larger market share by offering alternatives to CPAP therapy. The company’s new business model is anticipated to generate substantially higher revenue per case, despite the current transitional phase. Although there are risks associated with financing needs and potential dilution, the raised price target of $6.50 reflects confidence in the company’s market potential and product positioning, offering a promising upside for investors.